In vitro selection of novel RNA ligands that bind human cytomegalovirus and block viral infection

RNA

Volumn 6, Issue 4, 2000, Pages 571-583

  Wang, Jun ^a   Jiang, Hong ^a   Liu, Fenyong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiviral; Cytomegalovirus; In vitro selection; RNA aptamer; RNA ligand

Indexed keywords

LIGAND; RIBONUCLEASE; RNA; VIRUS ANTIGEN; VIRUS PROTEIN;

ARTICLE; BINDING AFFINITY; CYTOMEGALOVIRUS; IN VITRO STUDY; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RNA BINDING; SEQUENCE ANALYSIS; VIRUS INFECTION;

ANTIVIRAL AGENTS; BASE SEQUENCE; BINDING SITES; CELL LINE; CLONING, MOLECULAR; CYTOMEGALOVIRUS; DIRECTED MOLECULAR EVOLUTION; DNA, VIRAL; HERPESVIRUS 1, HUMAN; HUMANS; LIGANDS; PLAQUE ASSAY; PROTEIN BINDING; RIBONUCLEASES; RNA; SEQUENCE ANALYSIS, RNA; SUBSTRATE SPECIFICITY; THERMODYNAMICS; VIRAL ENVELOPE PROTEINS;

CYTOMEGALOVIRUS; HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 5;

EID: 0033995256     PISSN: 13558382     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1355838200992215     Document Type: Article

References (44)

1. Baldick CJ, Shenk T. 1996. Proteins associated with purified human cytomegalovirus particles. J Virol 70:6097-6105.
2. Britt WJ, Alford CA. 1996. Cytomegalovirus. In: Fields BN, Knipe DM, Howley PM, eds. Virology, 3rd ed. New York: Raven Press. pp 2493-2523.
3. Britt WJ, Auger D. 1986. Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus. J Virol 58:185-191.
4. Chee MS, Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, Horsnell T, Hutchison CA, Kouzarides T, Martignetti JA. 1990. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 154:125-169.
5. Chen D, Jiang H, Lee M, Liu F, Zhou H. 1999. Three-dimensional visualization of tegument/capsid interactions in intact human cytomegalovirus. Virology 260:10-16.
6. Compton T, Nowlin DM, Cooper NR. 1993. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology 193:834-841.
7. Cranage MP, Kouzarides T, Bankier AT, Satchwell S, Weston K, Tomlinson P, Barrell B, Hart H, Bell SE, Minson AC. 1986. Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EMBO J 5:3057-3063.
8. Ellington AD, Szostak JW. 1990. In vitro selection of RNA molecules that bind specific ligands. Nature 346:818-822.
9. Ellington AD, Szostak JW. 1992. Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures. Nature 355:850-852.
10. Gold L, Brown D, He Y, Shtatland T, Singer BS, Wu Y. 1997. From oligonucleotide shapes to genomic SELEX: Novel biological regulatory loops. Proc Natl Acad Sci USA 94:59-64.
11. Gold L, Polisky B, Uhlenbeck O, Yarus M. 1995. Diversity of oligonucleotide functions. Annu Rev Biochem 64:763-797.
12. Gretch DR, Kari B, Rasmussen L, Gehrz RC, Stinski MF. 1988. Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus. J Virol 62:875-881.
13. Guerrier-Takada C, Lumelsky N, Altman S. 1989. Specific interactions in RNA enzyme-substrate complexes. Science 246:1578-1584.
14. Homann M, Goringer HU. 1999. Combinatorial selection of high affinity RNA ligands to live African trypanosomes. Nucleic Acids Res 27:2006-2014.
15. Huber MT, Compton T. 1998. The human cytomegalovirus UL74 gene encodes the third component of the glycoprotein H-glycoprotein L-containing envelope complex. J Virol 72:8191-8197.
16. Irmiere A, Gibson W. 1985. Isolation of human cytomegalovirus intranuclear capsids, characterization of their protein constituents, and demonstration that the B-capsid assembly protein is also abundant in noninfectious enveloped particles. J Virol 56:277-283.
17. Jacobson MA, Drew WL, Feinberg J, O'Donnell JJ, Whitmore PV, Miner RD, Parenti D. 1991. Foscarnet therapy for ganciclovirresistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis 163:1348-1351.
18. Jellinek D, Green LS, Bell C, Lynott CK, Gill N, Vargeese C, Kirschenheuter G, McGee DP, Abesinghe P, Pieken WA. 1995. Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 34:11363-11372.
19. Joyce GF. 1992. Directed molecular evolution. Sci Am 267:90-97.
20. Kubik MF, Bell C, Fitzwater T, Watson SR, Tasset DM. 1997. Isolation and characterization of 2′-fluoro-, 2′-amino-, and 2′-fluoro-/amino-modified RNA ligands to human IFN-gamma that inhibit receptor binding. J Immunol 159:259-267.
21. Lee SW, Sullenger BA. 1997. Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nat Biotechnol 15:41-45.
22. Li L, Nelson JA, Britt WJ. 1997. Glycoprotein H-related complexes of human cytomegalovirus: Identification of a third protein in the gCIII complex. J Virol 71:3090-3097.
23. Lin Y, Nieuwlandt D, Magallanez A, Feistner B, Jayasena SD. 1996. High-affinity and specific recognition of human thyroid stimulating hormone (hTSH) by in vitro-selected 2′-amino-modified RNA. Nucleic Acids Res 24:3407-3414.
24. Lin Y, Qiu Q, Gill SC, Jayasena SD. 1994. Modified RNA sequence pools for in vitro selection. Nucleic Acids Res 22:5229-5234.
25. Liu F, Altman S. 1994. The differential evolution of substrates for an RNA enzyme in the presence and absence of its protein cofactor. Cell 77:1083-1100.
26. Liu F, Altman S. 1995. Inhibition of viral gene expression by the catalytic RNA subunit of RNase P from Escherichia coli. Genes & Dev 9:471-480.
27. Meyer H, Masuho Y, Mach M. 1990. The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. J Gen Virol 71:2443-2450.
28. Mocarski ES. 1996. Cytomegaloviruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Virology, 3rd ed. New York: Raven Press, pp 2447-2492.
29. Morris KN, Jensen KB, Julin CM, Weil M, Gold L. 1998. High affinity ligands from in vitro selection: Complex targets. Proc Natl Acad Sci USA 95:2902-2907.
30. Navarro D, Paz P, Tugizov S, Topp K, La Vail J, Pereira L. 1993. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology 197:143-158.
31. Pachl C, Probert WS, Hermsen KM, Masiarz FR, Rasmussen L, Merigan TC, Spaete RR. 1989. The human cytomegalovirus strain Towne glycoprotein H gene encodes glycoprotein p86. Virology 169:418-426.
32. Pagratis NC, Bell C, Chang YF, Jennings S, Fitzwater T, Jellinek D, Dang C. 1997. Potent 2′-amino-, and 2′-fluoro-2′-deoxyribo-nucleotide RNA inhibitors of keratinocyte growth factor. Nat Biotechnol 15:68-73.
33. Palestine AG, Polis MA, De Smet MD, Baird BF, Falloon J, Kovacs JA, Davey RT, Zurlo JJ, Zunich KM, Davis M. 1991. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 115:665-673.
34. Pan W, Craven RC, Qiu Q, Wilson CB, Wills JW, Golovine S, Wang JF. 1995. Isolation of virus-neutralizing RNAs from a large pool of random sequences. Proc Natl Acad Sci USA 92:11509-11513.
35. Pereira L, Hoffman M, Gallo D, Cremer N. 1982. Monoclonal antibodies to human cytomegalovirus: Three surface membrane proteins with unique immunological and electrophoretic properties specify cross-reactive determinants. Infect Immun 36:924-932.
36. Pieken WA, Olsen DB, Benseler F, Aurup H, Eckstein F. 1991. Kinetic characterization of ribonuclease-resistant 2′-modified hammer-head ribozymes. Science 253:314-317.
37. Qadri I, Navarro D, Paz P, Pereira L. 1992. Assembly of conformation-dependent neutralizing domains on glycoprotein B of human cytomegalovirus. J Gen Virol 73:2913-2921.
38. Rasmussen LE, Nelson RM, Kelsall DC, Merigan TC. 1984. Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc Natl Acad Sci USA 81:876-880.
39. Roizman B, Sears AE. 1996. Herpes simplex viruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Virology, 3rd ed. New York: Raven Press. pp 2231-2296.
40. Spaete RR, Thayer RM, Probert WS, Masiarz FR, Chamberlain SH, Rasmussen L, Merigan TC, Pachl C. 1988. Human cytomegalo-virus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 167:207-225.
41. Tuerk C, Gold L. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510.
42. Verma S, Eckstein F. 1998. Modified oligonucleotides: Synthesis and strategy for users. Annu Rev Biochem 67:99-134.
43. Wiegand TW, Williams PB, Dreskin SC, Jouvin MH, Kinet JP, Tasset D. 1996. High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. J Immunol 157:221-230.
44. Yang Q, Goldstein IJ, Mei HY, Engelke DR. 1998. DNA ligands that bind tightly and selectively to cellobiose. Proc Natl Acad Sci USA 95:5462-5467.